Survival curves demonstrating NY-ESO-1 to be a poor prognostic factor (A) and a predictive marker for benefit from adjuvant chemotherapy (B).

<p>Survival curves demonstrating NY-ESO-1 to be a poor prognostic factor (A) and a predictive marker for benefit from adjuvant chemotherapy (B).</p

Association of MAGE-A1, MAGE-A4 and MAGE-C1 expression and survival in the BR.10 study.

<p>Association of MAGE-A1, MAGE-A4 and MAGE-C1 expression and survival in the BR.10 study.</p

Clinicopathological features associated with CTA expression in two cohorts of patients.

<p>Clinicopathological features associated with CTA expression in two cohorts of patients.</p

Expression of N-ESO-1 and response to neoadjuvant chemotherapy (A).

<p>CR = Complete Response, PR = Partial Response, SD = Stable Disease, PD = Progressive Disease, NA = Not Assessable. Forest plot detailing factors associated with survival in patients who were treated in the post-operative cohort. Sq = Squamous Cell, ADC = Adenocarcinoma, ACT = Adjuvant Chemotherapy (B).</p

Multivariate analysis of factors associated with survival in patients treated with surgery initially.

<p>HR = hazard ratio, ACT = adjuvant chemotherapy, SQ = squamous cell, ADC = adenocarcinoma histology.</p